Asset profile
STRO-001
Antibody–drug conjugate
Evidence outlook · program status
On hold (2024-03), as a strategic decision by the sponsor
STRO-001 is Sutro Biopharma's anti-CD74 antibody-drug conjugate, taken through Phase 1 dose escalation in multiple myeloma and non-Hodgkin lymphoma. After its Greater China partner BioNova terminated its option and its own development in March 2024, Sutro suspended STRO-001 development; the filing says suspended, not terminated, so the program is recorded as on hold. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.